Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/10732748251317688 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Letter re: Blood-Based Multi-Cancer Early Detection Tests (MCEDs) as a Potential Approach to Address Current Gaps in Cancer Screening.
Cancer Control
January 2025
RNA Biology Lab, Saveetha Dental College and Hospital, Saveetha Institute of Medical and Technical Science (SIMATS), Saveetha University, Chennai, India.
A prospective multi-cohort study identifies and validates a 5-gene peripheral blood signature predictive of immunotherapy response in non-small cell lung cancer.
Mol Cancer
November 2024
Department of Quantitative Health Sciences, John A. Burns School of Medicine, University of Hawaii at Manoa, 651 Ilalo St, Honolulu, HI, 96813, USA.
Background: Immune checkpoint inhibitors (ICIs) have revolutionized the treatment landscape for non-small cell lung cancer (NSCLC). The variability in patient responses necessitates a blood-based, multi-cohort gene signature to predict ICI response in NSCLC.
Methods: We performed transcriptomic profiling of peripheral blood mononuclear cell (PBMC) and buffy coat (BC) samples from three independent cohorts of NSCLC patients treated with ICIs: a retrospective cohort (PMBCR, n = 59), a retrospective validation cohort (BC, n = 44), and a prospective validation cohort (PBMCP, n = 42).
The Landscape of Blood-based Screening Assays After the Fallacy of Theranos, Inc.
Clin Ther
September 2024
Department of Pediatrics, Women & Infants Hospital of Rhode Island, Providence, Rhode Island. Electronic address:
A metabolite-based liquid biopsy for detection of ovarian cancer.
Biomark Res
August 2024
Department of Biostatistics, The University of Texas M.D. Anderson Cancer Center, 6767 Bertner Street, Houston, TX, 77030, USA.
Article Synopsis
- A study in the UK showed that using CA125 blood tests and ultrasound for ovarian cancer didn't really lower deaths but helped find earlier cases.
- Researchers tested blood samples from women with ovarian cancer and controls to create a new test using 7 specific chemicals plus CA125.
- This new test was better at finding early-stage ovarian cancer, catching a good number of cases even when CA125 levels were low.
Harnessing extracellular vesicles using liquid biopsy for cancer diagnosis and monitoring: highlights from AACR Annual Meeting 2024.
J Hematol Oncol
July 2024
Key Laboratory of Novel Targets and Drug Study for Neural Repair of Zhejiang Province, School of Medicine, Hangzhou City University, Hangzhou, Zhejiang, China.
Liquid biopsy, an advanced technology for analyzing body fluid samples, is gaining traction in cancer diagnostics and monitoring. Blood-based liquid biopsy, particularly focusing on cell-free DNAs (cf-DNAs), circulating tumor cells (CTCs), and extracellular vesicles (EVs), has garnered significant attention. EVs stand out for their potential in tumor diagnosis, prognosis prediction, and treatment response assessment, owing to their stable molecular cargo and clear extraction process.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!